

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Medibio Limited
ABN	58 008 130 336

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Claude Solitario
Date of last notice	20 December 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Claude Solitario <Solitario Family A/C> (Director)
Date of change	13 July 2020
No. of securities held prior to change	<p>Direct 3,000 Fully Paid Ordinary Shares; 3,000,000 Unlisted Options exercisable at \$0.011 per option expiring 20 December 2023.</p> <p>Indirect 41,809,576 Fully Paid Ordinary Shares; 30,333,040 Quoted Options exercisable at \$0.03 each and expiring 1 December 2021; 3,000,000 Unlisted Options exercisable at \$0.014 expiring 13 June 2023; and 4,000,000 Unlisted Options exercisable at \$0.015 per option expiring 19 August 2024.</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Fully Paid Ordinary Shares
Number acquired	10,407,510
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.006 per share
No. of securities held after change	<p>Direct 3,000 Fully Paid Ordinary Shares; 3,000,000 Unlisted Options exercisable at \$0.011 per option expiring 20 December 2023.</p> <p>Indirect 52,217,086 Fully Paid Ordinary Shares; 30,333,040 Quoted Options exercisable at \$0.03 each and expiring 1 December 2021; 3,000,000 Unlisted Options exercisable at \$0.014 expiring 13 June 2023; and 4,000,000 Unlisted Options exercisable at \$0.015 per option expiring 19 August 2024.</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Fully Paid Ordinary Shares subscribed for and issued under the Company's Entitlement Offer as announced on 10 June 2020.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.